Sightsavers Logo
Research centre
  • Home
  • About us
  • Research approach
  • Research studies and publications
  • Evidence gap maps
Join in:
  • Join in: Facebook
  • Join in: Twitter
  • Join in: Instagram
  • Join in: LinkedIn
  • Join in: YouTube
  • Global
  • Close search bar
    Donate
    • Home
    • About us
    • Research approach
    • Research studies and publications
    • Evidence gap maps
    Research study

    Evaluating whether the ivermectin mass drug administration stoppage threshold for onchocerciasis can be safely adjusted

    On this page

    • Summary
    • Main objectives
    • Policy and practice implications
    • Methodology
    • Relevant links
    On this page
    • Summary
    • Main objectives
    • Policy and practice implications
    • Methodology
    • Relevant links

    Summary

    This study, benefiting from the technical support of Sightsavers in Benin, is part of a multi-country study (Benin, Ghana and Tanzania) supported by African Field Epidemiological Network (AFENET) in partnership with neglected tropical diseases (NTDs) departments of ministries of health and US Centers for Disease Control and Prevention.

    The study questions whether the World Health Organization’s (WHO) 2016 serological threshold of 0.1% for stopping mass drug administration (MDA) for onchocerciasis is too stringent.

    The primary aim is to assess whether an Ov-16 enzyme-linked immunosorbent assay (ELISA) seroprevalence of ≤%2 can be safely used as a threshold for stopping MDA without risk of recrudescence when the prevalence of O-150 polymerase chain reaction (PCR) positivity (Poolscreen) is <1/1000 (<0.1%) in parous blackflies or <1/2000 (0.05%) in all blackflies.

    Main objectives

    • Determine the seroprevalence of anti-Ov-16 antibodies by ELISA in children aged five to nine years at baseline and end of the study
    • Conduct annual serological assessments to establish any recrudescence in the study area after the cessation of MDA during the period between the initial and end-of-study assessments
    • Determine the initial infection rate of blackflies by O-150  (PCR) in pools of blackflies already collected by the national NTDs control programme in the study area to ensure that it is acceptable to stop MDA
    • Conduct annual entomological assessments to establish any recrudescence in the study area after the cessation of MDA using the new serological threshold in children

    Policy and practice implications

    The results will contribute to the evidence for keeping/updating the currently recognised serological threshold for stopping MDA.

    Methodology

    • Quantitative

    Relevant links

    Read more about the study

    Related tags

    Onchocerciasis
    Neglected tropical diseases (NTDs general)
    Benin
    Study details
    Start date
    1 January 2023
    Finish date
    31 December 2028
    Main contact
    Pelagie Boko-Collins
    NTD senior programme manager
    pboko@sightsavers.org
    Partners
    • AFENET
    • Benin Ministry of Health
    • l’Institut de Recherche Clinique du Bénin (IRCB)
    • Centre de Recherche Entomologique de Cotonou
    • US Centers for Disease Control and Prevention
    Funders
    US Centers for Disease Control and Prevention
    Countries
    Benin
    Themes/conditions
    Onchocerciasis
    Neglected tropical diseases (NTDs general)
    Study details
    Start date
    1 January 2023
    Finish date
    31 December 2028
    Main contact
    Pelagie Boko-Collins
    NTD senior programme manager
    pboko@sightsavers.org
    Partners
    • AFENET
    • Benin Ministry of Health
    • l’Institut de Recherche Clinique du Bénin (IRCB)
    • Centre de Recherche Entomologique de Cotonou
    • US Centers for Disease Control and Prevention
    Funders
    US Centers for Disease Control and Prevention
    Countries
    Benin
    Themes/conditions
    Onchocerciasis
    Neglected tropical diseases (NTDs general)

    Related research studies

    Research study

    Facility assessment for lymphatic filariasis-morbidity management and disability accessibility in Ghana

    Research study

    Rapid assessment of behavioural factors associated with delivery and uptake of care and services related to lymphatic filariasis

    Research study

    Potential mitigating role of ivermectin on the spread of Chlamydia trachomatis by Musca sorbens

    Sightsavers Logo
    Research centre
    • Join in:
    • Join in: Facebook
    • Join in: X
    • Join in: Instagram
    • Join in: LinkedIn
    • Join in: YouTube

    Protecting sight, fighting disease and promoting equality for all

  • Accessibility
  • Sightsavers homepage
  • Our policies
  • Media centre
  • Contact us
  • Jobs
  • Cookies and privacy Terms and conditions Modern slavery statement Safeguarding

    © 2025 by Sightsavers, Inc., Business Address for all correspondence: One Boston Place, Suite 2600, Boston, MA 02108.

    Our website uses cookies

    To make sure you have a great experience on our site, we’d like your consent to use cookies. These will collect anonymous statistics to personalise your experience.

    Manage preferences

    You have the option to enable non-essential cookies, which will help us enhance your experience and improve our website.

    Essential cookiesAlways on

    These enable our site to work correctly, for example by storing page settings. You can disable these by changing your browser settings, but some parts of our website will not work as expected.

    Analytics cookies

    To improve our website, we’d like to collect anonymous data about how you use the site, such as which pages you read, the device you’re using, and whether your visit includes a donation. This is completely anonymous, and is never used to profile individual visitors.

    Advertising cookies

    To raise awareness about our work, we’d like to show you Sightsavers adverts as you browse the web. By accepting these cookies, our advertising partners may use anonymous information to show you our adverts on other websites you visit. If you do not enable advertising cookies, you will still see adverts on other websites, but they may be less relevant to you. For info, see the Google Ads privacy policy.